IL1B and cardiac sarcoidosis: The ongoing pilot MAGIC-ART study will ascertain the feasibility of recruitment and enrollment of patients with cardiac sarcoidosis in two CTSA hubs and WASOG centers and test the tolerability of treatment with anakinra to assess how IL-1 blockade modulates systemic inflammation.